Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661387 | 1.00 | CASP1 (0.44) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL14009484 | 1.00 | CASP1 (0.44) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL4596673 | 0.94 | KMT2A (0.42) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL11276948 | 0.87 | KMT2A (0.50) | KMT2AALDH1A1 | |
| SCHEMBL9535176 | 0.86 | CXCL8 (0.46) | ABCB11ALDH1A1 | |
| SCHEMBL5327049 | 0.83 | CASP1 (0.56) | CASP1CYP2C19KMT2AALDH1A1 | |
| SCHEMBL30296727 | 0.82 | CA12 (0.43) | CASP1CYP2C19KMT2AALDH1A1HIF1A | |
| SCHEMBL26620210 | 0.82 | CA12 (0.43) | CASP1CYP2C19KMT2AALDH1A1HIF1A | |
| SCHEMBL6487230 | 0.81 | ALDH1A1 (0.56) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL30065589 | 0.80 | NR3C2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329751-B2 | Process for the preparation of clopidogrel | DIPHARMA S.P.A. (IT) | 2008-02-12 | — | — | US | claimed |
| EP-1501838-B1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | DIPHARMA FRANCIS SRL (IT) | 2007-04-11 | — | — | EP | claimed |
| US-20050143414-A1 | Process for the preparation of clopidogrel | DIPHARMA S.P.A. (IT) | 2005-06-30 | — | — | US | claimed |
| EP-1501838-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | Dinamite Dipharma S.p.A. (in abbreviated form Dipharma S.p.A.) (IT) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093276-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | DIPHARMA S.P.A. (IT) | 2003-11-13 | — | — | WO | claimed |
| US-20110087028-A1 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | ENZYTECH LTD. (KR) | 2011-04-14 | — | — | US | disclosed |
| EP-2298777-A2 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | Enzytech, Ltd. (KR) | 2011-03-23 | — | — | EP | disclosed |
| US-7329751-B2 | Process for the preparation of clopidogrel | DIPHARMA S.P.A. (IT) | 2008-02-12 | — | — | US | disclosed |
| EP-1501838-B1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | DIPHARMA FRANCIS SRL (IT) | 2007-04-11 | — | — | EP | disclosed |
| US-20050143414-A1 | Process for the preparation of clopidogrel | DIPHARMA S.P.A. (IT) | 2005-06-30 | — | — | US | disclosed |
| EP-1501838-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | Dinamite Dipharma S.p.A. (in abbreviated form Dipharma S.p.A.) (IT) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093276-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | DIPHARMA S.P.A. (IT) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143414-A1 | Process for the preparation of clopidogrel | CYP2C19, P2RY13, CYP2C9 | CASP1 3061/4885ABCB11 631/4885THRB 2174/4885 |
| US-20110087028-A1 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | PTGIS, PLA2G7, PTGIR | CASP1 2505/4885ABCB11 755/4885THRB 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.